this page is secure
Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance
OBJECTIVE: To determine the timing of pncA mutations that confer pyrazinamide (PZA) resistance in relation to mutations conferring resistance to isoniazid (INH) and rifampicin (RMP).
DESIGN: Isolates from two major urban centres—Paris (101 strains) and Shanghai (171 strains)—were investigated for the association of pncA mutations with resistance to drugs other than PZA.
RESULTS: The proportion of pncA mutations found in INH-monoresistant strains was not increased.
CONCLUSION: pncA mutations associated with PZA resistance were found almost exclusively in MDR-TB strains, underlining the importance of determining PZA resistance when treating MDR- or XDR-TB.
Keywords: drug resistance; pyrazinamide; tuberculosis
Document Type: Research Article
Affiliations: 1: Unité de Génétique Mycobactérienne, Institut Pasteur, Paris, France; Research and Specialised Diagnostics Unit, National Laboratory of Public Health, Libreville, Gabon 2: Key Laboratory of Medical Molecular Virology, Institutes of Biomedical Sciences and Institute of Medical Microbiology, Shanghai Medical College, Fudan University, Shanghai, China 3: Unité de Génétique Mycobactérienne, Institut Pasteur, Paris, France; Laboratoire de Bactériologie, Bichat-Claude Bernard Hospital, Paris, France 4: Unité de Génétique Mycobactérienne, Institut Pasteur, Paris, France 5: Department of Tuberculosis Control, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China 6: Laboratoire de Bactériologie, Bichat-Claude Bernard Hospital, Paris, France 7: Research and Specialised Diagnostics Unit, National Laboratory of Public Health, Libreville, Gabon 8: Laboratorio de Genética Molecular, Centro de Microbiologıa y Biologıa Celular, Instituto Venezolano de Investigaciones Cientificas, Caracas, Venezuela 9: Unité de Génétique Mycobactérienne, Institut Pasteur, Paris, France; Emerging Bacterial Pathogens Laboratory, Institut Pasteur of Shanghai, Shanghai, China
Publication date: 01 June 2015
The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.
The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- International Journal of Tuberculosis and Lung Disease
- Public Health Action
- Ingenta Connect is not responsible for the content or availability of external websites
Receive new issue alert